Vanda Pharmaceuticals (VNDA) Long-Term Investments (2011 - 2019)

Vanda Pharmaceuticals (VNDA) reported Long-Term Investments of $61.8 million for Q3 2019, up 393.94% sequentially from $12.5 million in Q2 2019.

Vanda Pharmaceuticals (VNDA) Long-Term Investments (2011 - 2019) Analysis & Trends

Vanda Pharmaceuticals (VNDA) has 2 years of Long-Term Investments data on file, last reported at $61.8 million in Q3 2019.

For the quarter ending Q3 2019, Long-Term Investments changed N/A year-over-year to $61.8 million; the trailing twelve-month figure through Sep 2019 stood at $61.8 million (changed N/A YoY), and the FY2011 full-year result was $19.0 million, changed N/A from the prior year.
Long-Term Investments advanced to $61.8 million in Q3 2019, from $12.5 million in the prior quarter.
In the past five years, Long-Term Investments ranged from a high of $61.8 million in Q3 2019 to a low of $12.5 million in Q2 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	505,194.89
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	5.75 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	9.79 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Vanda Pharmaceuticals	318.71 Mn	116.40 Mn	48.56 Mn	-

Download Data